Search results for " immunosuppression"

showing 9 items of 19 documents

Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference

2014

SummaryThe burden of infectious diseases both before and after liver transplantation is clearly attributable to the dysfunction of defensive mechanisms of the host, both as a result of cirrhosis, as well as the use of immunosuppressive agents.The present document represents the recommendations of an expert panel commended by the Italian Association for the Study of the Liver (AISF), on the prevention and management of infectious complications excluding hepatitis B, D, C, and HIV in the setting of liver transplantation.Due to a decreased response to vaccinations in cirrhosis as well as within the first six months after transplantation, the best timing for immunization is likely before transp…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationInfectionsInvasive fungal infectionPostoperative ComplicationsBacterial infectionsInvasive fungal infectionsTransplantation ImmunologyLower respiratory tract infectionHumansMedicineSmallpoxVoluntary Health AgenciesIntensive care medicineImmunosuppression TherapyViral infectionsInfection ControlCirrhosiLiver transplantationAttenuated vaccineHepatologybusiness.industryVaccinationHepatitis Bmedicine.diseaseVaccinationTransplantationBacterial infections; Cirrhosis; Invasive fungal infections; Liver transplantation; Viral infections; Humans; Immunosuppression; Infection; Infection Control; Italy; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Transplantation Immunology; Vaccination; Voluntary Health Agencies; HepatologyCirrhosisItalyViral infectionBacterial infections; Cirrhosis; Invasive fungal infections; Liver transplantation; Viral infectionsAISFImmunologyBacterial infectionInfectionbusinessImmunosuppression
researchProduct

Determinants of enhanced thromboxane biosynthesis in renal transplantation

2001

Determinants of enhanced thromboxane biosynthesis in renal transplantation.BackgroundDespite great improvement in patient and graft survival, the long-term morbidity and mortality in renal transplant recipients (RTRs) are still significant, with a high incidence of cardiovascular disease-related deaths.MethodsWe investigated thromboxane (TXA2) biosynthesis and endothelial and coagulative activation in 65 patients who received a renal transplant.ResultsThe rate of TXA2 biosynthesis (urinary 11-dehydro-TXB2 excretion largely reflects platelet TXA2 production in vivo) was significantly (P < 0.0001) higher in RTRs than in healthy subjects. Plasma von Willebrand factor (vWF) and thrombin-antithr…

MaleSettore MED/09 - Medicina InternaThromboxanegraft survivalThromboxanevon Willebrand factorImmunosuppressive AgentThromboxane A2chemistry.chemical_compoundReference ValuesRenal Dialysicardiovascular diseaseReference ValuePlateletPostoperative PeriodKidney transplantationKidneyimmunosuppressionnephrotoxicityThromboxanesMiddle AgedCholesterolmedicine.anatomical_structureNephrologyCyclosporineFemaleCardiovascular disease; Graft survival; Immunosuppression; Kidney transplantation; Nephrotoxicity; Von Willebrand factor; Adult; Antithrombin III; Cardiovascular Diseases; Cholesterol; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Peptide Hydrolases; Postoperative Period; Reference Values; Renal Dialysis; Thromboxanes; von Willebrand Factor; Kidney Transplantation; NephrologyImmunosuppressive AgentsHumancirculatory and respiratory physiologyAdultmedicine.medical_specialtyAntithrombin IIIUrologykidney transplantationFollow-Up StudieEndothelial activationRenal DialysismedicineHumansPlatelet activationcardiovascular disease; cardiovascular diseases; graft survival; immunosuppression; kidney transplantation; nephrotoxicity; von willebrand factorbusiness.industrymedicine.diseasecardiovascular diseasesTransplantationPeptide HydrolasechemistryImmunologybusinessFollow-Up StudiesPeptide HydrolasesKidney International
researchProduct

Impact of COVID-19 Pandemic in Children with CKD or Immunosuppression

2021

Infections are a major concern in children on KRT and with CKD. Risk factors include immunosuppression, multiple contacts in dialysis units, and hospital visits ([1][1]). Italy was one of the countries most affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak ([2][2

Malemedicine.medical_specialty2019-20 coronavirus outbreakAdolescentCoronavirus disease 2019 (COVID-19)EpidemiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.medical_treatmentglomerular disease030232 urology & nephrologyComorbidity030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineRisk Assessmentchronic kidney disease; COVID-19; immunosuppression; kidney transplantation; glomerular disease; childrenImmunocompromised Host03 medical and health sciences0302 clinical medicinechildrenRenal DialysisRisk FactorsInternal medicinePandemicHumansMedicineRenal Insufficiency ChronicChildCOVID-19; children; chronic kidney disease; glomerular disease; immunosuppression; kidney transplantation; Adolescent; Age Factors; Child; Child Preschool; Comorbidity; Female; Humans; Infant; Italy; Kidney Transplantation; Male; Renal Dialysis; Renal Insufficiency Chronic; Risk Assessment; Risk Factors; COVID-19; Immunocompromised HostKidney transplantationTransplantationimmunosuppressionbusiness.industryAge FactorsCOVID-19InfantOutbreakImmunosuppressionmedicine.diseaseKidney TransplantationResearch LettersItalyNephrologyChild PreschoolDialysis unitFemalebusinesschronic kidney diseaseClinical Journal of the American Society of Nephrology
researchProduct

Enhanced Drug Delivery to the Skin Using Liposomes

2018

Background:. Enhancing drug delivery to the skin has importance in many therapeutic strategies. In particular, the outcome in vascularized composite allotransplantation mainly depends on systemic immunosuppression to prevent and treat episodes of transplant rejection. However, the side effects of systemic immunosuppression may introduce substantial risk to the patient and are weighed against the expected benefits. Successful enhancement of delivery of immunosuppressive agents to the most immunogenic tissues would allow for a reduction in systemic doses, thereby minimizing side effects. Nanoparticle-assisted transport by low temperature–sensitive liposomes (LTSLs) has shown some benefit in a…

Oncologymedicine.medical_specialtyLiposomeSystemic immunosuppressionbusiness.industrylcsh:Surgerylcsh:RD1-811030230 surgerymedicine.diseaseVascularized Composite AllotransplantationTransplant rejection03 medical and health sciencesExperimental0302 clinical medicine030220 oncology & carcinogenesisInternal medicineDrug deliverymedicineSurgerybusinessPlastic and Reconstructive Surgery, Global Open
researchProduct

AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)

2016

After the first successful pregnancy in a liver transplant recipient in 1978, much evidence has accumulated on the course, outcomes and management strategies of pregnancy following liver transplantation. Generally, liver transplantation restores sexual function and fertility as early as a few months after transplant. Considering that one third of all liver transplant recipients are women, that approximately one-third of them are of reproductive age (18-49 years), and that 15% of female liver transplant recipients are paediatric patients who have a &gt;70% probability of reaching reproductive age, the issue of pregnancy after liver transplantation is rather relevant, and obstetricians, paedi…

Risk AssessmentFertility; Immunosuppression; Liver transplantation; PregnancyImmunosuppressive AgentPregnancyMedicalFertility; Immunosuppression; Liver transplantation; Pregnancy; Hepatology; GastroenterologyHumansFertility; Immunosuppression; Liver transplantation; Pregnancy; Gastroenterology; HepatologyObstetric Labor ComplicationSocieties MedicalLiver transplantationHepatologyPostpartum PeriodPregnancy OutcomeGastroenterologyFertility; Immunosuppression; Liver transplantation; Pregnancy; Contraception; Female; Fertility; Gastroenterology; Humans; Italy; Obstetric Labor Complications; Postpartum Period; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Risk Assessment; Societies Medical; Immunosuppressive Agents; Liver Transplantation; Pregnancy OutcomeFertility; Immunosuppression; Liver transplantation; Pregnancy; Contraception; Female; Fertility; Gastroenterology; Humans; Italy; Obstetric Labor Complications; Postpartum Period; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Risk Assessment; Societies Medical; Immunosuppressive Agents; Liver Transplantation; Pregnancy Outcome; Hepatology; GastroenterologyPregnancy ComplicationObstetric Labor ComplicationsPregnancy ComplicationsContraceptionFertilitysurgical procedures operativeItalyPractice Guidelines as TopicFemaleSocietiesImmunosuppressive AgentsImmunosuppressionHuman
researchProduct

Osteopontin shapes immunosuppression in the metastatic niche.

2014

Abstract The matricellular protein osteopontin (OPN, Spp-1) is widely associated with cancer aggressiveness when produced by tumor cells, but its impact is uncertain when produced by leukocytes in the context of the tumor stroma. In a broad study using Spp1−/− mice along with gene silencing in tumor cells, we obtained evidence of distinct and common activities of OPN when produced by tumor or host cells in a spontaneously metastatic model of breast cancer. Different cellular localization of OPN is associated with its distinct activities, being mainly secreted in tumor cells while intracellular in myeloid cells. OPN produced by tumor cells supported their survival in the blood stream, wherea…

STAT3 Transcription FactorCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsosteopontinCellContext (language use)Breast NeoplasmsT-Lymphocytes RegulatoryMonocytesMicestomatognathic systemCell Line TumormedicineImmune ToleranceAnimalsHumansMyeloid CellsOsteopontinNeoplasm MetastasisCellular localizationImmunosuppression TherapyMice Inbred BALB CMice Inbred C3HimmunosuppressionbiologyArginaseInterleukin-6Matricellular proteinCancerosteopontin; niche; immunosuppressionmedicine.diseaseMice Inbred C57BLnichemedicine.anatomical_structureOncologyTumor progressionCell culturebiology.proteinFemale
researchProduct

P658 The Inflammatory Bowel Disease Disability Index (IBD-DI) in ulcerative colitis is related to disease activity, need of immunosuppressive therapy…

2017

medicine.medical_specialtybusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisGastroenterologyInflammatory bowel diseaseDisease activityTherapeutic immunosuppression03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicinemedicine030211 gastroenterology & hepatology030212 general & internal medicinebusinessJournal of Crohn's and Colitis
researchProduct

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

2019

Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy that involves abnormal processing of von-Willebrand factor (vWF) and results in multiple organ dysfunction. Although aTTP remains a very unpredictable disease, risk factors for death include older age, lactate dehydrogenase (LDH) levels &gt;10x the upper limit of normal (ULN), and cerebral involvement (i.e., the French severity score) (Benhamou et al. Haematologica 2012;97:1181-1186). In addition, raised cardiac troponin-I (cTnI) levels of &gt;2.5 µg/L have also been linked with a higher risk of mortality or refractoriness (Benhamou et al. J Thromb Haemost 2015;1…

medicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyBiochemistryTherapeutic immunosuppressionDisease severityInternal medicineSeverity of illnessmedicinePlatelet Count measurementThrombotic MicroangiopathiesIn patientCaplacizumabbusinessBlood
researchProduct

Is COVID‐19 infection more severe in kidney transplant recipients?

2021

International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney transplant recipients from the French Registry of Solid Organ Transplant (n=306) and a single-center cohort of non-transplant patients (n=795). An analysis was performed among subgroups matched for age and risk factors for severe Covid-19 or mortality. Severe Covid-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death.Transplant recipients were younger and had more comorbidities compared to…

medicine.medical_treatment[SDV]Life Sciences [q-bio]MESH: Registries*AucunMESH: Comorbidity030230 surgerylaw.inventionchemistry.chemical_compound0302 clinical medicinelawcardiovascular diseaseMESH: Risk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesclinical research / practiceImmunology and AllergyCumulative incidencePharmacology (medical)kidney transplantation / nephrologyMESH: IncidenceMESH: AgedUnivariate analysisMESH: France / epidemiologyMESH: Middle AgedMESH: Transplant Recipients / statistics & numerical data*Acute kidney injuryIntensive care unit3. Good healthMESH: COVID-19 / epidemiologyCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesglomerular filtration rate (GFR)kidney failure / injurymedicine.medical_specialtyinfection and infectious agents - viralinfectious diseaseBrief CommunicationMESH: Graft Rejection / prevention & control03 medical and health sciencesInternal medicineDiabetes mellitusMESH: Severity of Illness IndexMESH: COVID-19 / diagnosis*medicineHumansMESH: SARS-CoV-2Mechanical ventilationCreatinineTransplantationMESH: Humansbusiness.industrySARS-CoV-2MESH: Graft Rejection / epidemiology*COVID-19MESH: Retrospective Studiesmedicine.diseaseKidney TransplantationTransplant RecipientsMESH: Maleimmunosuppressive regimensMESH: Immunosuppressive Agents / therapeutic useMESH: Pandemics*MESH: Propensity Score*chemistryReinfectionMESH: Immunosuppression / methodsMESH: Intensive Care UnitsbusinessMESH: FemaleMESH: Kidney Transplantation*
researchProduct